2002
DOI: 10.1016/s0140-6736(02)11922-2
|View full text |Cite
|
Sign up to set email alerts
|

Effects of corticosteroid use on treatment of solid tumours

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

2
77
0
1

Year Published

2003
2003
2022
2022

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 104 publications
(80 citation statements)
references
References 18 publications
2
77
0
1
Order By: Relevance
“…In fact, the authors detected around 40% cortisol levels in knockout mice relative to control mice after cortisone challenge 40 . In addition, Dex has been reported to render non-haematological cancer cells more resistant to antitumour drugs [41][42][43][44] . However, clinical evidence for this drug resistance induction remains unclear.…”
Section: Discussionmentioning
confidence: 99%
“…In fact, the authors detected around 40% cortisol levels in knockout mice relative to control mice after cortisone challenge 40 . In addition, Dex has been reported to render non-haematological cancer cells more resistant to antitumour drugs [41][42][43][44] . However, clinical evidence for this drug resistance induction remains unclear.…”
Section: Discussionmentioning
confidence: 99%
“…3 GCs are also widely used as comedication in cancer therapy of solid malignant tumors due for their effectiveness in treating the malignant tumor or treatment-related oedema, inflammation, pain, electrolyte imbalance, to stimulate appetite, to prevent nausea and emesis or toxic reactions caused by cytotoxic treatment. 1,4 Before, during and after chemotherapy of solid malignant tumors GCs are given at varying doses to reduce acute toxicity, particularly hyperemesis and to protect normal tissue, e.g., bone marrow progenitor cells, 5 of cancer patients against the long-term effects of genotoxic drugs. 4 The cell type-specific and GC-mediated protection of normal tissues and solid tumors from apoptosis induction by cytotoxic agents and its potential clinical implications have been mostly unknown so far and are just about to be recognized as a more common phenomenon.…”
Section: Introductionmentioning
confidence: 99%
“…1,4 Before, during and after chemotherapy of solid malignant tumors GCs are given at varying doses to reduce acute toxicity, particularly hyperemesis and to protect normal tissue, e.g., bone marrow progenitor cells, 5 of cancer patients against the long-term effects of genotoxic drugs. 4 The cell type-specific and GC-mediated protection of normal tissues and solid tumors from apoptosis induction by cytotoxic agents and its potential clinical implications have been mostly unknown so far and are just about to be recognized as a more common phenomenon. 6,7 However, little is known about how GCs might affect the response of solid, nonhematological tumors in patients undergoing cancer chemo-or radiotherapy.…”
Section: Introductionmentioning
confidence: 99%
“…The role of PET in the diagnosis of pancreatic cancer is unclear with significant false positives and negatives 5. The improved oxygenation following methylprednisolone therapy may have related to decreased oedema and secretions such as seen when used with lymphangitis carcinomatosis 6 or to the anti‐inflammatory and tumour angiogenesis suppressive effects of corticosteroids 7.…”
Section: Discussionmentioning
confidence: 99%